Moderna
MRNA
$195.00
-2.17%
Moderna is a commercial-stage biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines, with a portfolio spanning infectious disease, oncology, cardiovascular disease, and rare genetic diseases; as of March 2026 it had 25 mRNA development candidates in clinical studies. Moderna is best understood as a platform company rather than a single-product biotech: its mRNA-LNP delivery technology, validated at global scale by its COVID-19 vaccine, is being redeployed across a broad pipeline, and its personalized cancer vaccine (mRNA-4157) with Merck has become the central pillar of the equity story. The investor narrative has pivoted decisively away from COVID-era revenue decay toward oncology, with positive Phase 3 melanoma data, a return to quarterly profitability in Q3 2026, and inclusion in the Nasdaq-100 driving a dramatic re-rating. At the same time, the debate is now about durability and valuation: an 18% single-day plunge on reports of leaked melanoma vaccine data and a subsequent ~25% pullback from October highs illustrate how much optimism is embedded in the shares, while sell-side analysts remain split between bulls pricing in a cancer-franchise transformation and skeptics focused on cash burn and commercialization risk.…
MRNA
Moderna
$195.00
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating: Hold. Moderna is a genuine platform-inflection story — Q3 2026 revenue of $1.313 billion grew 29.2% YoY, net income swung to $162 million (EPS $0.40) from a -$1.343 billion loss in Q1, and gross margin recovered to 75.8% — but at $196.79 the stock trades roughly 19% above the $165.32 average analyst target with a consensus recommendation of "hold" (2.91 mean; only 4 Buy, 16 Hold, 3 Sell). The core thesis is that the oncology pivot (mRNA-4157 with Merck) has re-rated the equity 689.7% over one year, yet the price now embeds much of that promise while trailing free cash flow remains -$1.949 billion.
Supporting evidence cuts both ways. On the positive side, the profitability inflection is real: operating income turned positive at $130 million (9.9% margin) versus -$815 million in Q2, R&D moderated to $583 million from $651 million, the current ratio is a healthy 3.29, and debt-to-equity is just 0.151. On valuation, the 5.90x PS sits near the low end of its own recent band (versus 58.8x at Q3 2026 and 191.3x at Q2 2026) and P/B of 1.33x is historically cheap, while consensus 2027 revenue of $8.22 billion (range $6.80–$11.20 billion) and average forward EPS of $4.13 imply a multi-year ramp. But the negative trailing PE (-4.06x) and forward PE (-48.1x) confirm the premium is pure pipeline option value, and the -16% implied downside to the average target caps near-term upside.
Three risks could invalidate the thesis: (1) a melanoma data disappointment like the October 22 leak that triggered an 18% single-day drop, (2) continued cash burn — $1.196 billion of cash against -$1.949 billion TTM FCF and a $1.911 billion working-capital outflow in Q3 — and (3) valuation compression given the 6.8x analyst target spread ($45 to $305). This Hold would upgrade to Buy on a decisive melanoma Phase 3 readout confirming the $305 bull case or a pullback toward the $140–150 consolidation, and would downgrade to Sell on a break below the $180 support shelf or FCF remaining negative through 2027. Verdict: fairly valued to modestly overvalued relative to consensus and history — the fundamentals have improved faster than the multiple, but the price has run ahead of the models.
Sign up to view all
MRNA 12-Month Price Forecast
The forward view is genuinely balanced: the fundamental inflection is real and operating leverage is arriving, but the equity has already priced a large share of the oncology promise after a 689.7% one-year gain, leaving the stock above consensus fair value and vulnerable to binary pipeline news. The 6.8x analyst target spread ($45 to $305) and EPS range of $3.20 to $6.07 signal low conviction, so the base case is consolidation toward the $150–180 zone rather than a smooth continuation. I would upgrade to bullish on a clean confirmatory mRNA-4157 readout or a pullback toward the $140s that restores risk/reward, and downgrade to bearish on a break below $180, a melanoma miss, or free cash flow still deeply negative into 2027. Until one of those resolves, the risk/reward is asymmetric to the downside near term despite the improving fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $164.53 and implied upside of -15.6% versus the current price.
Average Target
$164.53
23 analysts
Implied Upside
-15.6%
vs. current price
Analyst Count
23
covering this stock
Price Range
$45 - $305
Analyst target range
Coverage is broad but the consensus is decidedly cautious: 19 analysts cover MRNA with a distribution of 4 Buy, 16 Hold, and 3 Sell, yielding a recommendation of "hold" and a recommendation mean of 2.91 (where 3.0 is a pure hold). The average target price of $165.32 implies roughly -16% downside from the current $196.79, meaning the stock is trading above the consensus fair value after its 690% run — a classic signal that price has outrun analyst models. Sentiment leans neutral-to-bearish despite the rally, and the recent institutional actions confirm the split: Argus upgraded to Buy from Hold (Aug 28), while Citigroup downgraded to Sell from Neutral (Sep 30), Rothschild downgraded to Sell from Neutral (Sep 3), and William Blair cut to Market Perform from Outperform (Oct 27), with Piper Sandler (Overweight) and Goldman Sachs (Neutral) reiterating.
The target range is extraordinarily wide — from a low of $45.00 to a high of $305.00, a 6.8x spread that signals very high uncertainty and low conviction. The high target of $305 assumes the personalized cancer vaccine succeeds commercially, multiple expansion on oncology-platform economics, and revenue scaling toward the $11.2 billion high end of consensus estimates; the low target of $45 prices in melanoma data disappointment, continued cash burn, competitive losses to BioNTech and others, and a return to COVID-era revenue decay. The estimated EPS range of $3.20 to $6.07 (average $4.13) further illustrates the dispersion in profitability assumptions. With the stock at $196.79 versus a $165.32 average target and only 4 of 19 analysts bullish, the risk/reward is asymmetric to the downside near term — the market has already priced in much of the good news, and the wide spread means investors should expect continued violent swings around pipeline catalysts rather than a smooth re-rating.
Bulls vs Bears: MRNA Investment Factors
The bear case currently has stronger near-term evidence: the stock trades ~19% above the $165.32 consensus target with only 4 of 19 analysts bullish, free cash flow is -$1.949 billion, and the one-month trend has turned negative (-13.3% versus SPY -4.73%). The bull case rests on a genuine fundamental inflection — Q3 2026 revenue +29.2% YoY, a $162 million profit, and 75.8% gross margin — plus an oncology pipeline that has already driven a 690% re-rating and Nasdaq-100 inclusion. The single most important tension is whether the personalized cancer vaccine (mRNA-4157) commercializes on the timeline implied by the $305 high target or disappoints as the leaked melanoma data episode hinted; that one variable, more than COVID revenue decay or cash burn, determines whether the current price is a floor or a peak. Until pipeline data resolves that question, the risk/reward is asymmetric to the downside near term, with violent swings around catalysts the base case rather than a smooth re-rating.
Bullish
- Q3 2026 swing to profitability: Q3 2026 net income of $162 million (EPS $0.40 diluted) reversed Q2's -$782 million loss and Q1's -$1.343 billion loss, with gross margin recovering to 75.8% from 35.9% and -145.5% in the prior two quarters. Operating income turned positive at $130 million (9.9% margin) versus -$815 million in Q2, evidence that operating leverage is arriving as revenue scales.
- Revenue inflecting 29% YoY: Q3 2026 revenue of $1.313 billion grew 29.2% year-over-year versus $1.016 billion in Q3 2025 and rebounded massively from Q2 2026's $145 million. The $2.597 billion product-sales base supports consensus 2027 revenue estimates of $8.22 billion (range $6.80–$11.20 billion), implying the market expects a multi-year ramp.
- Oncology pipeline is the re-rating driver: Positive Phase 3 melanoma data for mRNA-4157 with Merck has repositioned MRNA as a cancer-platform story, and the stock's 689.7% one-year gain reflects that pivot. With 25 mRNA development candidates in clinical studies as of March 2026, the pipeline offers optionality beyond COVID that peers like BioNTech have struggled to match.
- Balance sheet and liquidity intact: Debt-to-equity is low at 0.151 and the current ratio is a strong 3.29, while Q3 2026 was funded with $2.745 billion of net financing inflows. The company also demonstrated in Q4 2025 that the model can generate cash (operating cash flow +$951 million, FCF +$912 million), so the current negative FCF reflects working-capital timing and a $2.99 billion debt repayment rather than structural cash destruction.
Bearish
- Price above consensus target: At $196.79 the stock trades roughly 19% above the $165.32 average analyst target, implying about -16% downside to consensus fair value after a 690% run. Only 4 of 19 analysts rate it Buy (16 Hold, 3 Sell) with a recommendation mean of 2.91, a classic signal that price has outrun analyst models.
- Cash burn remains severe: Trailing free cash flow is -$1.949 billion, with Q3 2026 operating cash flow of -$1.559 billion and FCF of -$1.606 billion driven by a $1.911 billion working-capital outflow. Cash fell to $1.196 billion from $1.724 billion at the start of Q3, leaving the company dependent on external capital markets despite the profitability headline.
- Extreme earnings volatility: Quarterly EPS swung from -$3.40 (Q1 2026) to -$1.96 (Q2) to +$0.40 (Q3), and revenue ranged from $145 million to $1.313 billion across the same three quarters. Trailing net margin of -145.2%, operating margin of -158.1%, and ROE of -32.6% show the cumulative losses still dominate the trailing picture, making single-quarter extrapolation dangerous.
- Valuation is pure pipeline option value: With trailing PE of -4.06x, forward PE of -48.1x, and negative margins, the 5.90x PS premium is entirely a bet on oncology scaling rather than earnings. The 6.8x spread in analyst targets ($45 to $305) and EPS estimates ($3.20 to $6.07) signals very low conviction and wide dispersion in profitability assumptions.
MRNA Technical Analysis
Moderna is in an extraordinary, parabolic uptrend: the stock is up 689.7% over the past year and 537.7% year-to-date, and at $196.79 it sits at roughly 67.7% of its 52-week range (low $22.28, high $280.80). That positioning reflects powerful momentum rather than overextension at the highs — the stock is about 30% below its 52-week peak — but the vertical nature of the move (from ~$46 in late May to ~$269 at the November 9 peak) means the trend is mature and increasingly dependent on news flow rather than gradual accumulation. The 52-week low of $22.28 underscores how completely sentiment has reversed; this is a recovery that became a momentum mania, and traders should treat the long-term trend as intact but fragile.
Short-term momentum has clearly decelerated and turned negative: the stock is down 13.3% over the past month and 4.8% on the day (previous close $206.80 to $196.79), a sharp divergence from the +47.6% three-month and +319.8% six-month gains. Relative strength tells the same story — MRNA has outperformed SPY by 679.1 percentage points over one year and 51.9 points over three months, but has lagged the S&P by 8.5 points over the past month (SPY -4.73% vs. MRNA -13.27%). This one-month underperformance against both its own trend and the market is a classic mean-reversion signal after a vertical advance, amplified by the October 22 melanoma data-leak episode that produced an 18% single-day drop; the stock has now printed a sequence of lower highs from $269 (Nov 9) to $250.83, $231.35, $223.37, $215.27, $206.80, and $196.79, a textbook short-term downtrend within a longer-term uptrend.
Key technical levels are unusually wide given the volatility: support sits at the psychological $180–190 zone (the late-September/early-October breakout shelf around $182–$194), with deeper support at the ~$140 area (August–September consolidation) and the 52-week low of $22.28 as the extreme downside reference; resistance is the all-time-recent high of $280.80, with intermediate resistance at $269 and $258. A decisive break below $180 would confirm a failed breakout and likely target the $140s, while a reclaim of $230+ would signal the pullback was merely consolidation. With a beta of 1.166, MRNA is roughly 17% more volatile than the market on a smoothed basis, but its realized volatility is far higher — the max drawdown of -34.16% and daily swings of 10–30% around catalysts mean position sizing should assume fat tails, not the modest beta figure.
Beta
1.17
1.17x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$24-$281
Price range past year
Annual Return
+772.1%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | -20.7% | -9.7% |
| 3m | +34.4% | -9.9% |
| 6m | +316.0% | -7.5% |
| 1y | +772.1% | +4.7% |
| ytd | +531.9% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
The revenue trajectory is inflecting sharply upward after a brutal trough: Q3 2026 revenue of $1.313 billion grew 29.2% year-over-year versus $1.016 billion in Q3 2025, and marked a massive sequential rebound from Q2 2026's $145 million and Q1 2026's $389 million. The multi-quarter pattern shows extreme seasonality and lumpiness — Q1 2026 revenue collapsed to $389 million with a negative gross margin of -145.5% (cost of revenue of $955 million against a $566 million gross loss), while Q4 2025 posted $678 million and Q3 2025 $1.016 billion. The Q3 2026 print (reported November 6) beat estimates and, combined with the $2.597 billion product sales figure and the oncology pivot, supports the bull case that Moderna is transitioning from a COVID-dependent story to a diversified commercial franchise — though the wild quarter-to-quarter swings mean a single quarter should not be extrapolated.
Profitability has swung from deeply negative to positive in a single quarter: Q3 2026 net income was $162 million (EPS $0.40 diluted, $0.38), a dramatic reversal from Q2 2026's -$782 million loss (EPS -$1.96) and Q1 2026's -$1.343 billion loss (EPS -$3.40). Gross margin recovered to 75.8% in Q3 2026 from 35.9% in Q2 2026 and a negative -145.5% in Q1 2026, while operating income turned positive at $130 million (9.9% operating margin) versus -$815 million in Q2. The trailing metrics remain ugly — net margin of -145.2%, operating margin of -158.1%, ROE of -32.6%, and ROA of -9.96% — reflecting the cumulative losses of the prior three quarters, but the direction of travel is unmistakable: R&D spending moderated to $583 million in Q3 from $651 million in Q2 and $649 million in Q1, and the company is now demonstrating operating leverage as revenue scales.
Balance-sheet health is solid but cash burn is the key risk: debt-to-equity is low at 0.151 and the current ratio is a strong 3.29, but trailing free cash flow is deeply negative at -$1.949 billion, with Q3 2026 operating cash flow of -$1.559 billion and FCF of -$1.606 billion driven largely by a $1.911 billion working-capital outflow (receivables of -$1.351 billion) and a $2.99 billion debt repayment. Cash at period end fell to $1.196 billion from $1.724 billion at the start of Q3, and the company funded itself with $2.745 billion of net financing inflows — a reminder that Moderna still depends on external capital markets despite the profitability headline. The Q4 2025 quarter showed the model can generate cash (operating cash flow of +$951 million, FCF +$912 million), so the swing to negative FCF in 2026 reflects working-capital timing and debt paydown rather than structural cash destruction, but with $1.2 billion of cash and a -$1.9 billion TTM FCF, liquidity management remains a genuine fundamental risk.
Quarterly Revenue
$1.3B
2026-09
Revenue YoY Growth
+29.2%
YoY Comparison
Gross Margin
75.8%
Latest Quarter
Free Cash Flow
$-2.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Because trailing net income is negative (EPS -$0.246, trailing PE -4.06), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 5.90x as the primary metric, supplemented by the forward PE of -48.1x (also negative, reflecting expected losses on a GAAP basis) and the EV/Sales of 32.77x. The gap between the 5.90x trailing PS and the 32.77x EV/Sales is largely explained by the market-cap discrepancy in the data (the metrics file shows $11.47 billion while the identity file shows $88.16 billion), so the EV/Sales figure should be treated with caution; the more reliable read is that at ~5.9x sales on a $2.6 billion product-sales base, the market is pricing in substantial revenue growth — consistent with consensus 2027 revenue estimates of $8.22 billion (range $6.80–$11.20 billion) and forward EPS estimates averaging $4.13.
Peer comparison is constrained by the absence of an explicit industry-average multiple in the provided valuation data, but the internal spread is instructive: PS of 5.90x against a PEG of 0.187 and a price-to-book of 1.33x. The 1.33x P/B is remarkably low for a company that has rallied 690% — it implies the market cap is only modestly above book value, which is consistent with the large accumulated losses depressing equity — while the 5.90x PS is a premium multiple that assumes the oncology franchise scales. Relative to large-cap biotech peers that typically trade at 4–8x sales when profitable and growing, Moderna sits in the middle of the range, but its negative margins (-145% net, -158% operating) mean the premium is entirely a pipeline option value rather than an earnings-based valuation; the discount to book value is the more defensible anchor for value investors.
Historical context shows the stock is nowhere near its own valuation extremes: the PS ratio of 5.90x compares with 58.8x at Q3 2026 (per historical ratios), 191.3x at Q2 2026, and 51.6x at Q1 2026 — meaning the current multiple is near the low end of its recent band, a direct consequence of the revenue recovery rather than multiple compression. The P/B of 1.33x is likewise near the bottom of its historical range (versus 11.29x at Q3 2026 and 4.10x at Q2 2026), and the PE of -4.06x is negative and therefore not comparable to the 120.4x trailing PE recorded at Q3 2026. The interpretation is nuanced: on sales and book, the stock looks cheaper than it has in a year, but that is because the denominator (revenue and equity) has recovered while the price has run — the market is pricing optimistic oncology expectations into a still-unprofitable business, and the historical band offers little comfort given how violently the fundamentals have swung.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~192x
vs. Industry Avg
29.3x
Industry PE ~29.3x*
EV/EBITDA
-4.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on cash burn and revenue concentration. Trailing free cash flow is -$1.949 billion against just $1.196 billion of period-end cash, and Q3 2026 alone consumed $1.559 billion of operating cash flow, largely a $1.911 billion working-capital outflow including $1.351 billion of receivables. The company plugged the gap with $2.745 billion of net financing inflows and a $2.99 billion debt repayment, meaning it still depends on capital markets despite reporting a $162 million quarterly profit. Revenue is also dangerously lumpy and product-concentrated: quarterly revenue ranged from $145 million (Q2 2026) to $1.313 billion (Q3 2026), and Q1 2026 posted a -145.5% gross margin on $955 million of cost of revenue against $389 million of sales, so a single weak quarter can erase the profitability narrative.
Market and competitive risks are dominated by valuation compression and pipeline execution. At 5.90x sales with negative trailing and forward earnings (PE -4.06x, forward PE -48.1x), the entire premium is pipeline option value, and the 6.8x spread between the $45 low and $305 high analyst targets shows how little consensus exists on fair value. The October 22 melanoma data-leak episode produced an 18% single-day drop and a subsequent ~25% pullback from October highs, demonstrating that expectations are priced for perfection; Citigroup, Rothschild, and William Blair all downgraded in the recent cycle. Competition is real — BioNTech's cancer-vaccine setback shows the category can disappoint, but a Moderna-specific clinical miss would be far more damaging given the stock's 689.7% one-year run, and with a beta of 1.166 plus realized daily swings of 10–30% around catalysts, sector rotation out of high-multiple biotech would hit MRNA disproportionately.
The worst-case scenario is a melanoma data disappointment combined with continued cash burn and a return to COVID-era revenue decay. In that chain, the stock would retest the August–September consolidation around $140 and potentially the $45 analyst low target, which would represent roughly -29% to -77% from the current $196.79; a full retrace toward the 52-week low of $22.28 would be catastrophic but is the extreme reference given the -34.16% max drawdown already recorded. A more realistic adverse path is a break below the $180–190 support shelf, which would confirm a failed breakout and likely target the $140s — about -29% from here — while the $45 low target implies -77%. Position sizing should assume fat tails rather than the modest 1.166 beta.
FAQ
Ranked by severity, the first risk is binary pipeline execution: the entire re-rating rests on mRNA-4157, and the October 22 melanoma data-leak episode already demonstrated an 18% single-day loss, with the analyst low target of $45 implying -77% from here. Second is cash burn and financing: TTM free cash flow is -$1.949 billion against $1.196 billion of period-end cash, and Q3 2026 required $2.745 billion of net financing inflows, so a capital raise would be dilutive at an inopportune moment. Third is earnings volatility and revenue concentration — quarterly revenue ranged from $145 million (Q2 2026) to $1.313 billion (Q3 2026), and Q1 2026 posted a -145.5% gross margin, meaning one weak quarter can erase the profitability narrative. Fourth is valuation and macro sensitivity: with a beta of 1.166, a -34.16% max drawdown, and a 6.8x spread in analyst targets, sector rotation out of high-multiple biotech would hit MRNA disproportionately, as the -13.3% one-month decline versus SPY's -4.73% already shows.
The 12-month view splits into three scenarios: a 50% base case of $150–180 as the stock consolidates toward the $165.32 average target and the $180–190 breakout shelf while revenue tracks the $8.22 billion consensus midpoint; a 25% bull case of $280.80–305.00 if confirmatory melanoma Phase 3 data is clean and gross margin holds near 75.8%, retesting the 52-week high; and a 25% bear case of $45–140 if the vaccine disappoints or cash burn persists, breaking support toward the August–September consolidation. The base case is most likely because the fundamental inflection is real but already largely priced after a 689.7% one-year gain, and analyst conviction is low (recommendation mean 2.91, target range $45 to $305). The key assumption behind the base case is that no major melanoma data surprise occurs and free cash flow narrows from -$1.949 billion without forcing dilutive financing; a clean readout would shift probability mass to the bull case, while a miss would make the bear case dominant.
Traditional earnings multiples are unusable here — trailing PE is -4.06x and forward PE is -48.1x because GAAP earnings are negative — so price-to-sales at 5.90x is the primary anchor, alongside a price-to-book of 1.33x. On sales the stock is near the low end of its own recent band (58.8x at Q3 2026, 191.3x at Q2 2026, 51.6x at Q1 2026), and P/B of 1.33x is historically cheap versus 11.29x at Q3 2026, but that reflects recovered revenue and equity denominators rather than a cheap price. Against consensus the stock is modestly overvalued: $196.79 versus a $165.32 average target, with the market effectively capitalizing a 2027 revenue ramp to $8.22 billion (range $6.80–$11.20 billion) and forward EPS averaging $4.13. The 5.90x PS implies the market expects oncology commercialization to succeed; if it does, the multiple is defensible, and if it stalls, the same multiple on a shrinking COVID base would look expensive.
From a pure risk/reward standpoint the setup is only moderately attractive at $196.79: the stock trades about 19% above the $165.32 average analyst target, implying roughly -16% downside to consensus fair value, and only 4 of 19 analysts rate it Buy with a recommendation mean of 2.91. The upside case is real — Q3 2026 revenue grew 29.2% YoY to $1.313 billion, net income swung to $162 million, and gross margin reached 75.8%, while the $305 high target implies about +55% if the melanoma vaccine delivers clean Phase 3 data. The biggest downside risk is a pipeline disappointment like the October 22 data leak that produced an 18% single-day drop, compounded by TTM free cash flow of -$1.949 billion against $1.196 billion of cash. It can be a good buy for risk-tolerant investors building a position gradually around the $140–150 consolidation or after a clean confirmatory readout, but it is a poor entry for anyone who needs near-term margin of safety given the 6.8x analyst target spread ($45 to $305).
MRNA is structurally a long-term holding candidate but practically a volatile trading vehicle, so the right answer depends on position sizing and tolerance for drawdowns. The growth stage is early-commercial with a 25-candidate mRNA pipeline, no dividend (payout ratio 0), and earnings visibility that is poor quarter-to-quarter — EPS swung from -$3.40 in Q1 2026 to +$0.40 in Q3 2026 — which makes short-term trading around catalysts tempting but dangerous given 10–30% daily swings and a -34.16% max drawdown. A beta of 1.166 understates realized volatility, and the -13.3% one-month move versus SPY's -4.73% shows how quickly momentum reverses. For long-term investors, a minimum holding period of 18–24 months is appropriate to span the confirmatory melanoma readout and the 2027 revenue ramp toward $8.22 billion, ideally built in tranches around the $140–150 consolidation rather than at $196.79, which is ~19% above the $165.32 consensus target.

